|
10 Oct 2019 |
Avacta Group plc Enters Collaboration and Option Agreement With ADC Therapeutics
|
|
10 Oct 2019 |
UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases
|
|
09 Oct 2019 |
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
|
|
08 Oct 2019 |
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
|
|
08 Oct 2019 |
Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
|
|
08 Oct 2019 |
4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines
|
|
07 Oct 2019 |
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
|
|
04 Oct 2019 |
Goldfinch Bio Announces Licensing Agreement with Takeda for CB1 Monoclonal Antibody for the Treatment of Rare and Metabolic Kidney Diseases
|
|
02 Oct 2019 |
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
|
|
02 Oct 2019 |
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
|
01 Oct 2019 |
Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology
|
|
01 Oct 2019 |
Numab and Eisai Enter Into a Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer
|
|
01 Oct 2019 |
Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma
|
|
01 Oct 2019 |
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
|
|
01 Oct 2019 |
Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio
|
|
30 Sep 2019 |
Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
|
|
27 Sep 2019 |
Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform
|
|
27 Sep 2019 |
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
|
|
27 Sep 2019 |
Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna
|
|
25 Sep 2019 |
Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas
|
|
24 Sep 2019 |
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs
|
|
24 Sep 2019 |
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
|
|
20 Sep 2019 |
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
|
|
19 Sep 2019 |
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
|
|
19 Sep 2019 |
Y-Trap Enters Collaboration with Merck KGaA, Darmstadt, Germany, to Develop Novel Antibody-Ligand Traps for Immuno-Oncology
|
